Payment overview · 2025
General Payments
$357.04
17 reported records · 11 companies
Healthcare provider profile · identity verified
Jake Dailey, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · VIDALIA, GA · NPI 1447792478
Verified facts
What the public records show
CMS Open Payments records show Jake Dailey, FNP received $357.04 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.28 | 20.0% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $62.28 | 17.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.30 | 13.0% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $37.48 | 10.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.46 | 10.5% | 2 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $19.74 | 5.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.97 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.19 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.48 | 4.9% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $14.34 | 4.0% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.52 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.04 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.28 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $62.28 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.14 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $46.30 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | Octapharma USA, Inc., PFIZER INC. | $31.82 | 2 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methylprednisolone | Methylprednisolone | 169 | 145 |
| Cefuroxime | Cefuroxime Axetil | 151 | 132 |
| Azithromycin | Azithromycin | 141 | 132 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 135 | 121 |
| Gabapentin | Gabapentin | 134 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 29 |
| Omeprazole | Omeprazole | 124 | 31 |
| Fluconazole | Fluconazole | 114 | 85 |
| Losartan Potassium | Losartan Potassium | 107 | 32 |
| Simvastatin | Simvastatin | 105 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 23 |
| Synthroid | Levothyroxine Sodium | 100 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 99 | 25 |
| Metformin Hcl | Metformin Hcl | 98 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 88 |
| Montelukast Sodium | Montelukast Sodium | 95 | 19 |
| Allopurinol | Allopurinol | 92 | 18 |
| Furosemide | Furosemide | 92 | 35 |
| Prednisone | Prednisone | 89 | 69 |
| Famotidine | Famotidine | 84 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 82 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 22 |
| Celecoxib | Celecoxib | 76 | 13 |
| Lorazepam | Lorazepam | 74 | 18 |
| Azelastine Hcl | Azelastine Hcl | 70 | 34 |
| Meloxicam | Meloxicam | 67 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 27 |
| Potassium Chloride | Potassium Chloride | 57 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 16 |
| Lansoprazole | Lansoprazole | 55 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 13 |
| Sertraline Hcl | Sertraline Hcl | 52 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 19 |
| Tramadol Hcl | Tramadol Hcl | 50 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 40 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Cephalexin | Cephalexin | 34 | 32 |
| Atenolol | Atenolol | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Lisinopril | Lisinopril | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Nystatin | Nystatin | 15 | 14 |
| Carvedilol | Carvedilol | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | 14 |
| Trulicity | Dulaglutide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.04 · 17 records | ABBVIE INC. | CUTAQUIG, Dexcom G6 Transmitter, Flector, Licart, MOUNJARO, PANZYGA, Prolastin-C Liquid, QULIPTA, Ryaltris, SHINGRIX, Tirosint, UBRELVY, VERQUVO, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error